Treatment of IgA nephropathy: An overview

Nephrology

Volumn 3, Issue SUPPL. 2, 1997, Pages s725-s730

  D'Amico, Giuseppe ^a  

^a SAN CARLO BORROMEO HOSPITAL   (Italy)

Author keywords

ACE inhibitors; Fish oil; Steroids; Therapy

Indexed keywords

CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; FISH OIL; STEROID; WARFARIN;

CLINICAL PROTOCOL; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFICACY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STEROID THERAPY; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0030720990     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1797.1997.tb00291.x     Document Type: Conference Paper

References (36)

1. D'Amico G. Epidemiology, clinical and prognostic indices in IgA nephropathy. Nephrology 1997; 3: 13-17.
2. Bené MC, Hurault de Ligny B, Kessler M, Foliguet B, Faure GC. Tonsils in IgA nephropathy. Contrib. Nephrol. 1993; 104: 153-61.
3. D'Amico G, Imbasciati E, Barbiano di Belgioioso G et al. Idiopathic IgA mesangial nephropathy. Clinical and histological study of 374 patients. Medicine 1985; 64: 49-60.
4. Coppo R, Roccatello D, Amore A et al. Effects of gluten-free diet in primary IgA nephropathy. Clin. Nephrol. 1990; 33: 72-86.
5. Ferri C, Puccini R, Longobardo G et al. Low-antigen-content diet in the treatment of patients with IgA nephropathy. Nephrol. Dial. Transplant. 1993; 8: 1193-8.
6. Bazzi C, Sinico RA, Petrini C et al. Low doses of drugs able to alter intestinal mucosal permeability to food antigens (5-aminosalicylic acid and sodium chromoglycate) do not reduce proteinuria in patients with IgA nephropathy: A preliminary noncontrolled trial. Nephron 1992; 61: 192-5.
7. Egido J, Rivera F, Sancho J, Barat A, Hernando L. Phenytoin in IgA nephropathy: a long term controlled trial. Nephron 1984; 38: 30-9.
8. Clarkson AR, Seymour AE, Woodroffe AJ, McKenzie PE, Chan Y-L, Wootton AM. Controlled trial of phenytoin therapy in IgA nephropathy. Clin. Nephrol. 1980; 13: 215-8.
9. Lai KN, Lai FM, Ho CP, Chan KW. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: A long-term controlled trial. Clin. Nephrol. 1986; 26: 174-80.
10. Kohayashi Y, Fujii K, Hiki Y, Tateno S, Kurokawa A, Kamiyama M. Steroid therapy in IgA nephropathy: A retrospective study in heavy proteinuric cases. Nephron 1988; 48: 12-7.
11. Kobayashi Y, Fujii K, Hiki Y, Tateno S. Steroid therapy in IgA nephropathy: a prospective pilot study in moderate proteinuric cases. Q. J. Med. 1986; 234: 935-43.
12. Goumenos D, Ahuja M, Shortland JR, Brown CB. Can immunosuppressive drugs slow the progression of IgA nepropathy? Nephrol. Dial. Transplant. 1995; 10: 1173-81.
13. Waldo FB, Alexander R, Wyatt RJ, Kohaut EC. Alternate-day prednisone therapy in children with IgA-associated nephritis. Am. J. Kidney Dis. 1989; 13: 55-60.
14. Julian BA, Baker C. Alternate-day prednisone therapy in IgA nephropathy. Contrib. Nephrol. 1993; 104: 198-206.
15. Schena FR, Montenegro M, Scivittaro V. Meta-analysis of randomized controlled trials in patients with IgA nephropathy (Berger's disease). Nephrol. Dial. Transplant. 1990;5: 47-52.
16. Woo KT, Edmundson RPS, Yap HK et al. Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis. Clin. Neprol. 1987; 27: 56-64.
17. Woo KT, Chiang GSC, Lim CH. Follow-up renal biopsies in IgA nephritic patients on triple therapy. Clin. Nephrol. 1987; 27: 304-5.
18. Walker RG, Yu SH, Owen JE, Kincaid-Smith P. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole, and warfarin: A two year prospective trial. Clin. Nephrol. 1990; 34: 103-7.
19. Lai KN, Lai FM, Li PKT, Vallance-Owen J. Cyclosporin treatment of IgA nephropathy: a short-term controlled trial. BMJ 1987; 295: 1165-8.
20. De Caterina R, Endres S, Kristensen ST, Schmidt EB. n-3 Fatty acids and renal diseases. Am. J. Kidney Dis. 1994; 24: 397-415.
21. Cheng IKP, Chan PCK, Chan MK. The effect of fish-oil dietary supplement on the progression of mesangial IgA glomerulo-nephritis. Nephrol. Dial. Transplant. 1990;5: 241-6.
22. Bennett WM, Walker RG, Kincaid-Smith P. Treatment of IgA nephropathy with eico-sapentanoic acid (EPA): A two-year prospective trial. Clin. Nephrol. 1989; 31: 128-31.
23. Pettersson EE, Rekola S, Berglund L et al. Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: A prospective, double-blind, randomized study. Clin. Nephrol. 1994; 41: 183-90.
24. Donadio JV, Bergstralh EJ, Offord KP, Spencer DC, Holley KE. A controlled trial of fish oil in IgA nephropathy. N. Engl. J. Med. 1994; 331: 1194-9.
25. van Ypersele de Strihou C. Fish oil for IgA nephropathy? N. Engl. J. Med. 1994; 331: 1227-9.
26. Clarkson AR, Woodroffe AJ, Bannister KM, Odum J, Thomas A. Therapy in IgA nephropathy. In: Bené MC, Faure GC, Kessler M (eds) IgA Nephropathy: The 25th year Contrib. Nephrol. Karger, Basel, 1993 189-97.
27. Rostoker G, Desvaux-Belghiti D, Pilatte Y et al. High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schönlein purpura. Ann. Intern. Med. 1994; 120: 476-84.
28. Remuzzi A, Perticucci E, Ruggenenti P, Mosconi L, Limonta M, Remuzzi G. Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int. 1991; 39: 1267-73.
29. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J. Clin. Invest. 1986; 77: 1993-2000.
30. Rekola S, Bergstrand A, Bucht H. Deterioration rate in hypertensive IgA nephropathy: Comparison of a converting enzyme inhibitor and β-blocking agents. Nephron 1991; 59: 57-60.
31. Cattran DC, Greenwood C, Ritchie S. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am. J. Kidney Dis. 1994; 23: 247-54.
32. Maschio G, Cagnoli L, Claroni F et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. Nephrol. Dial. Transplant. 1994; 9: 265-9.
33. Yorioka T, Suehiro T, Yasuoka N, Hashimoto K, Kawada M. Polymorphism of the angiotensin converting enzyme gene and clinical aspects of IgA nephropathy. Clin. Nephrol. 1995; 44: 80-5.
34. Harden PN, Geddes C, Rowe PA et al. Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy. Lancet 1995; 345: 1540-2.
35. Yoshida H, Mitarai T, Kawamura T et al. Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J. Clin. Invest. 1995; 96: 2162-9.
36. Hunley TE, Julian BA, Phillips JA et al. Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy. Kidney Int. 1996; 49: 571-7.